All articles by Vidya Sagar Maddela

Vidya Sagar Maddela

US FDA approves GSK’s Shingrix vaccine in prefilled syringe format

The new format of Shingrix eliminates the need for making separate vials, streamlining the prevention of shingles (herpes zoster) in adults.

Samsung Bioepis, Harrow partner for ophthalmology biosimilars

Once the commercial licence transfer is completed, Harrow will take full responsibility for the commercialisation of Byooviz and Opuviz in the US.

SandboxAQ, iOncologi collaborate on AI-driven drug discovery

The partnership will focus on developing a high-fidelity mRNA vaccine leveraging SandboxAQ’s AI-driven drug discovery platform and iOncologi’s immunotherapy expertise.

Sanofi gains FDA fast-track status for SAR446597 in geographic atrophy

Sanofi’s SAR446597 is designed to address the underlying pathophysiology of complement-mediated retinal diseases, providing long-term expression of therapeutic proteins.

Acumen, JCR partner to enhance Alzheimer’s therapy delivery

The partnership combines Acumen’s expertise in amyloid beta oligomer-selective antibodies with JCR’s blood-brain barrier-penetrating technology, to improve AD treatment delivery.

Biocon Biologics gets FDA approval for interchangeable insulin Kirsty

Kirsty is a rapid-acting human insulin analogue designed to enhance glycaemic control in adults and children with diabetes mellitus.

Bayer gets FDA approval for finerenone to treat heart failure with LVEF

Finerenone is the only non-steroidal mineralocorticoid receptor antagonist approved in the US for both chronic kidney disease with diabetes and heart failure with LVEF.

ViiV Healthcare expands MPP licensing deal for long-acting HIV treatment

The move aims to facilitate the development, manufacture, and supply of generic versions of CAB LA for HIV treatment in 133 countries.

RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs

The site offers on-demand manufacturing with direct delivery to the patient’s treatment facility within just three days of release after production.

Elegen, Nutcracker unveil cell-free RNA manufacturing pilot

The initiative aims to enhance the accessibility and scalability of PCTs by reducing turnaround times and bioburden and endotoxin risks.